#METABOLOMICS WORKBENCH epannkuk_20231205_105308 DATATRACK_ID:4490 STUDY_ID:ST003000 ANALYSIS_ID:AN004928 PROJECT_ID:PR001870
VERSION             	1
CREATED_ON             	December 8, 2023, 12:04 pm
#PROJECT
PR:PROJECT_TITLE                 	Effect of Antibiotic Administration on Metabolomic Radiation Biodosimetry
PR:PROJECT_SUMMARY               	Development of novel biodosimetry assays and medical countermeasures is needed
PR:PROJECT_SUMMARY               	to obtain a level of radiation preparedness in the event of malicious or
PR:PROJECT_SUMMARY               	accidental mass exposures to ionizing radiation (IR). For biodosimetry,
PR:PROJECT_SUMMARY               	metabolic profiling with mass spectrometry (MS) platforms has identified several
PR:PROJECT_SUMMARY               	small molecules in easily accessible biofluids that are promising for dose
PR:PROJECT_SUMMARY               	reconstruction. As our microbiome has profound effects on biofluid metabolite
PR:PROJECT_SUMMARY               	composition, it is of interest how variation in the host microbiome may affect
PR:PROJECT_SUMMARY               	metabolomics based biodosimetry. Here, we chemically ‘knocked out’ the
PR:PROJECT_SUMMARY               	microbiome of male and female C57BL/6 mice (Abx mice) and then irradiated (0, 3,
PR:PROJECT_SUMMARY               	or 8 Gy) them to determine the role of the host microbiome on biofluid radiation
PR:PROJECT_SUMMARY               	signatures (3 d serum).
PR:INSTITUTE                     	Georgetown University
PR:LAST_NAME                     	Pannkuk
PR:FIRST_NAME                    	Evan
PR:ADDRESS                       	3970 Reservoir Rd, NW New Research Build, washington dc, District of Columbia,
PR:ADDRESS                       	20057, USA
PR:EMAIL                         	elp44@georgetown.edu
PR:PHONE                         	2026875650
#STUDY
ST:STUDY_TITLE                   	Effects of Microbiome Depletion on Radiation Biodosimetry Metabolomics
ST:STUDY_SUMMARY                 	Development of novel biodosimetry assays and medical countermeasures is needed
ST:STUDY_SUMMARY                 	to obtain a level of radiation preparedness in the event of malicious or
ST:STUDY_SUMMARY                 	accidental mass exposures to ionizing radiation (IR). For biodosimetry,
ST:STUDY_SUMMARY                 	metabolic profiling with mass spectrometry (MS) platforms has identified several
ST:STUDY_SUMMARY                 	small molecules in easily accessible biofluids that are promising for dose
ST:STUDY_SUMMARY                 	reconstruction. As our microbiome has profound effects on biofluid metabolite
ST:STUDY_SUMMARY                 	composition, it is of interest how variation in the host microbiome may affect
ST:STUDY_SUMMARY                 	metabolomics based biodosimetry. Here, we chemically ‘knocked out’ the
ST:STUDY_SUMMARY                 	microbiome of male and female C57BL/6 mice (Abx mice) and then irradiated (0, 3,
ST:STUDY_SUMMARY                 	or 8 Gy) them to determine the role of the host microbiome on biofluid radiation
ST:STUDY_SUMMARY                 	signatures (3 d serum).
ST:INSTITUTE                     	Georgetown University
ST:LAST_NAME                     	Pannkuk
ST:FIRST_NAME                    	Evan
ST:ADDRESS                       	3970 Reservoir Rd, NW New Research Build, washington dc, District of Columbia,
ST:ADDRESS                       	20057, USA
ST:EMAIL                         	elp44@georgetown.edu
ST:PHONE                         	2026875650
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
SU:GENDER                        	Male and female
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7588M	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_09; RAW_FILE_NAME=NEG_09
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7579M	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_10; RAW_FILE_NAME=NEG_10
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7634F	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_11; RAW_FILE_NAME=NEG_11
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7636F	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_12; RAW_FILE_NAME=NEG_12
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7614F	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_13; RAW_FILE_NAME=NEG_13
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7628F	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_14; RAW_FILE_NAME=NEG_14
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7635F	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_15; RAW_FILE_NAME=NEG_15
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7642F	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_16; RAW_FILE_NAME=NEG_16
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7650F	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_17; RAW_FILE_NAME=NEG_17
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7639F	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_22; RAW_FILE_NAME=NEG_22
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7589M	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_23; RAW_FILE_NAME=NEG_23
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7594M	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_24; RAW_FILE_NAME=NEG_24
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7582M	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_25; RAW_FILE_NAME=NEG_25
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7632F	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_26; RAW_FILE_NAME=NEG_26
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7600M	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_27; RAW_FILE_NAME=NEG_27
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7626F	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_28; RAW_FILE_NAME=NEG_28
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7637F	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_29; RAW_FILE_NAME=NEG_29
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7596M	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_30; RAW_FILE_NAME=NEG_30
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7595M	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_31; RAW_FILE_NAME=NEG_31
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7631F	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_36; RAW_FILE_NAME=NEG_36
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7607M	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_37; RAW_FILE_NAME=NEG_37
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7616F	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_38; RAW_FILE_NAME=NEG_38
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7581M	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_39; RAW_FILE_NAME=NEG_39
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7604M	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_40; RAW_FILE_NAME=NEG_40
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7633F	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_41; RAW_FILE_NAME=NEG_41
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7640F	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_42; RAW_FILE_NAME=NEG_42
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7608M	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_43; RAW_FILE_NAME=NEG_43
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7643F	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_44; RAW_FILE_NAME=NEG_44
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7623F	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_45; RAW_FILE_NAME=NEG_45
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7625F	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_50; RAW_FILE_NAME=NEG_50
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7641F	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_51; RAW_FILE_NAME=NEG_51
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7603M	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_52; RAW_FILE_NAME=NEG_52
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7644F	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_53; RAW_FILE_NAME=NEG_53
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7592M	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_54; RAW_FILE_NAME=NEG_54
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7586M	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_55; RAW_FILE_NAME=NEG_55
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7622F	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_56; RAW_FILE_NAME=NEG_56
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7630F	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_57; RAW_FILE_NAME=NEG_57
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7587M	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_58; RAW_FILE_NAME=NEG_58
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7599M	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_59; RAW_FILE_NAME=NEG_59
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7619F	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_64; RAW_FILE_NAME=NEG_64
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7605M	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_65; RAW_FILE_NAME=NEG_65
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7638F	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_66; RAW_FILE_NAME=NEG_66
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7583M	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_67; RAW_FILE_NAME=NEG_67
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7591M	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_68; RAW_FILE_NAME=NEG_68
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7627F	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_69; RAW_FILE_NAME=NEG_69
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7618F	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_70; RAW_FILE_NAME=NEG_70
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7602M	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_71; RAW_FILE_NAME=NEG_71
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7598M	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_72; RAW_FILE_NAME=NEG_72
SUBJECT_SAMPLE_FACTORS           	wo_0Gy	7617F	Antibiotics:wo | Irradiation:0Gy	RAW_FILE_NAME=POS_73; RAW_FILE_NAME=NEG_73
SUBJECT_SAMPLE_FACTORS           	w_8Gy	7606M	Antibiotics:w | Irradiation:8Gy	RAW_FILE_NAME=POS_78; RAW_FILE_NAME=NEG_78
SUBJECT_SAMPLE_FACTORS           	w_0Gy	7597M	Antibiotics:w | Irradiation:0Gy	RAW_FILE_NAME=POS_79; RAW_FILE_NAME=NEG_79
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7590M	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_80; RAW_FILE_NAME=NEG_80
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7621F	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_81; RAW_FILE_NAME=NEG_81
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7629F	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_82; RAW_FILE_NAME=NEG_82
SUBJECT_SAMPLE_FACTORS           	w_3Gy	7601M	Antibiotics:w | Irradiation:3Gy	RAW_FILE_NAME=POS_83; RAW_FILE_NAME=NEG_83
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7585M	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_84; RAW_FILE_NAME=NEG_84
SUBJECT_SAMPLE_FACTORS           	wo_8Gy	7593M	Antibiotics:wo | Irradiation:8Gy	RAW_FILE_NAME=POS_85; RAW_FILE_NAME=NEG_85
SUBJECT_SAMPLE_FACTORS           	wo_3Gy	7624F	Antibiotics:wo | Irradiation:3Gy	RAW_FILE_NAME=POS_86; RAW_FILE_NAME=NEG_86
#COLLECTION
CO:COLLECTION_SUMMARY            	On day 3, mice were euthanized by CO2 inhalation, blood was collected by cardiac
CO:COLLECTION_SUMMARY            	puncture, and tissues were collected. Tissues were flash frozen. Serum samples
CO:COLLECTION_SUMMARY            	were prepared using BD Microtainer Tube (REF 365967) with ~100 µL of whole
CO:COLLECTION_SUMMARY            	blood added to each tube, kept at room temperature for 30 min, then spun at
CO:COLLECTION_SUMMARY            	1300× g at 4 °C for 10 min. All tissues and biofluids were stored at −80 °C
CO:COLLECTION_SUMMARY            	until analysis.
CO:SAMPLE_TYPE                   	Blood (serum)
#TREATMENT
TR:TREATMENT_SUMMARY             	We used 8 week old male and female C57BL/6 mice that were purchased from Charles
TR:TREATMENT_SUMMARY             	River Laboratories (Frederick, MD) and were assigned to sham, 3 Gy, or 8 Gy
TR:TREATMENT_SUMMARY             	cohorts. A control group (Abx-con) did not receive antibiotics in drinking water
TR:TREATMENT_SUMMARY             	and a treatment group (Abx) received broad-spectrum antibiotics (n=10 per group,
TR:TREATMENT_SUMMARY             	half male half female) (S1 Fig). Mice were provided with deionized water ad
TR:TREATMENT_SUMMARY             	libitum either with or without the antibiotic cocktail (enrofloxacin [0.575
TR:TREATMENT_SUMMARY             	mg/ml] and ampicillin [1 mg/ml]) for 8 days prior to irradiation [24]. Mice were
TR:TREATMENT_SUMMARY             	irradiated in an acrylic, 12-slot mouse pie cage (MPC-1, Braintree Scientific,
TR:TREATMENT_SUMMARY             	Braintree, MA) on top of a specimen turntable (XD1905-0000, Precision X-Ray Inc,
TR:TREATMENT_SUMMARY             	Branford, CT) and 0, 3 or 8 Gy X-ray irradiated (1.67 Gy/min; X-Rad 320,
TR:TREATMENT_SUMMARY             	Precision X-Ray Inc.; filter, 0.75 mm tin/ 0.25 mm copper/1.5 mm aluminum). For
TR:TREATMENT_SUMMARY             	Abx-con mice, spot urines (>100 µL) were collected 1 d prior to irradiation and
TR:TREATMENT_SUMMARY             	at 1 and 3 d post-irradiation (fecal samples collected 1 d prior to irradiation
TR:TREATMENT_SUMMARY             	and at 3 d post-irradiation).
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	On day 3, mice were euthanized by CO2 inhalation, blood was collected by cardiac
SP:SAMPLEPREP_SUMMARY            	puncture, and tissues were collected. Tissues were flash frozen. Serum samples
SP:SAMPLEPREP_SUMMARY            	were prepared using BD Microtainer Tube (REF 365967) with ~100 µL of whole
SP:SAMPLEPREP_SUMMARY            	blood added to each tube, kept at room temperature for 30 min, then spun at
SP:SAMPLEPREP_SUMMARY            	1300× g at 4 °C for 10 min. All tissues and biofluids were stored at −80 °C
SP:SAMPLEPREP_SUMMARY            	until analysis.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	The LC and MS conditions for serum was as follows: LC solvent A (water/0.1%
CH:CHROMATOGRAPHY_SUMMARY        	formic acid [FA]), solvent B (acetonitrile/0.1% FA), and solvent C
CH:CHROMATOGRAPHY_SUMMARY        	(isopropanol/0.1% FA). Operating conditions for ESI were, capillary voltage 3
CH:CHROMATOGRAPHY_SUMMARY        	kV, cone voltage 30 V, desolvation temperature 500°C, desolvation gas flow 600
CH:CHROMATOGRAPHY_SUMMARY        	L/Hr. The gradient for serum was: 4 min 98% A 2% B, 4 min 40% A 60% B, 1.5 min
CH:CHROMATOGRAPHY_SUMMARY        	2% A 98% B, 2 min 11.8% B 88.2% C, 0.5 min 50% A 50% B, and 1 min 98% A 2% B at
CH:CHROMATOGRAPHY_SUMMARY        	a flow rate of 0.5 ml/min, column temp 60 °C (S3 Fig).
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Waters Acquity
CH:COLUMN_NAME                   	Waters ACQUITY UPLC BEH C18 (50 x 2.1mm,1.7um)
CH:SOLVENT_A                     	100% water; 0.1% formic acid
CH:SOLVENT_B                     	100% acetonitrile; 0.1% formic acid
CH:SOLVENT_C                     	100% isopropanol; 0.1% formic acid
CH:FLOW_GRADIENT                 	4 min 98% A 2% B, 4 min 40% A 60% B, 1.5 min 2% A 98% B, 2 min 11.8% B 88.2% C,
CH:FLOW_GRADIENT                 	0.5 min 50% A 50% B, and 1 min 98% A 2% B
CH:FLOW_RATE                     	0.5 ml/min
CH:COLUMN_TEMPERATURE            	60
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Waters Xevo-G2-S
MS:INSTRUMENT_TYPE               	QTRAP
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	NEGATIVE
MS:MS_COMMENTS                   	Operating conditions for ESI were, capillary voltage 3 kV, cone voltage 30 V,
MS:MS_COMMENTS                   	desolvation temperature 500°C, desolvation gas flow 600 L/Hr.
MS:MS_RESULTS_FILE               	ST003000_AN004928_Results.txt	UNITS:peak area	Has m/z:Yes	Has RT:Yes	RT units:Minutes
#END